Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners.
| Revenue (Most Recent Fiscal Year) | $56.83M |
| Net Income (Most Recent Fiscal Year) | $-24.02M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.25 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -64.98% |
| Net Margin (Trailing 12 Months) | -42.26% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -36.02% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.60 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.27 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.76 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-3.14 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.68 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.37 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.17 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 7.62M |
| Free Float | 7.00M |
| Market Capitalization | $13.95M |
| Average Volume (Last 20 Days) | 0.02M |
| Beta (Past 60 Months) | 1.21 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.97% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |